全文获取类型
收费全文 | 21766篇 |
免费 | 1178篇 |
国内免费 | 112篇 |
专业分类
耳鼻咽喉 | 202篇 |
儿科学 | 405篇 |
妇产科学 | 401篇 |
基础医学 | 3142篇 |
口腔科学 | 332篇 |
临床医学 | 2044篇 |
内科学 | 5124篇 |
皮肤病学 | 471篇 |
神经病学 | 2641篇 |
特种医学 | 1337篇 |
外国民族医学 | 1篇 |
外科学 | 3024篇 |
综合类 | 116篇 |
一般理论 | 8篇 |
预防医学 | 1136篇 |
眼科学 | 281篇 |
药学 | 1308篇 |
中国医学 | 22篇 |
肿瘤学 | 1061篇 |
出版年
2023年 | 156篇 |
2022年 | 223篇 |
2021年 | 500篇 |
2020年 | 290篇 |
2019年 | 413篇 |
2018年 | 466篇 |
2017年 | 349篇 |
2016年 | 490篇 |
2015年 | 507篇 |
2014年 | 715篇 |
2013年 | 967篇 |
2012年 | 1522篇 |
2011年 | 1498篇 |
2010年 | 926篇 |
2009年 | 873篇 |
2008年 | 1335篇 |
2007年 | 1335篇 |
2006年 | 1278篇 |
2005年 | 1290篇 |
2004年 | 1147篇 |
2003年 | 1048篇 |
2002年 | 1005篇 |
2001年 | 370篇 |
2000年 | 347篇 |
1999年 | 358篇 |
1998年 | 226篇 |
1997年 | 187篇 |
1996年 | 113篇 |
1995年 | 128篇 |
1994年 | 101篇 |
1993年 | 78篇 |
1992年 | 142篇 |
1991年 | 114篇 |
1990年 | 145篇 |
1989年 | 153篇 |
1988年 | 136篇 |
1987年 | 119篇 |
1986年 | 131篇 |
1985年 | 130篇 |
1984年 | 94篇 |
1983年 | 85篇 |
1979年 | 101篇 |
1978年 | 74篇 |
1977年 | 83篇 |
1975年 | 74篇 |
1974年 | 70篇 |
1973年 | 90篇 |
1972年 | 75篇 |
1971年 | 87篇 |
1969年 | 66篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. 总被引:1,自引:0,他引:1
BACKGROUND: The incidence figures for ulcerative colitis (UC) and Crohn's disease (CD) have been difficult to interpret, and geographical variations may be due to differences in classification criteria and study design. Few studies have based the incidence on prospective systematic follow up to confirm the initial diagnosis. METHODS: Between 1990 and 1993, in a prospective incidence study of inflammatory bowel disease (IBD) in south eastern Norway, 527 cases of UC, 228 cases of CD, 36 cases of indeterminate colitis (IND), and 55 cases of possible IBD were identified, yielding an annual incidence of 13.6, 5.9, 0.9, and 1.4 per 10(5) respectively. The diagnosis and all clinical data were reviewed by two gastroenterologists independently of each other. One to two years after diagnosis, all patients were offered a clinical follow up in which the initial diagnosis was assessed. RESULTS: Between the time of diagnosis and the follow up, 16 patients had died, four of complications related to IBD. Of the remaining 830 patients, 98% (814/830) were available for follow up, 93% (772/830) attended a clinical examination which included a colonoscopy in 77% (637/830), and the remainder had had a telephone interview, or reassessment based on hospital records, or both. Twenty seven patients were reclassified as not having IBD (3%), and 65 patients were characterised as possible IBD (8%). Of the patients initially classified as UC, 88% had their diagnosis confirmed, compared with 91% with an initial diagnosis of CD. In patients with indeterminate colitis, 33% were classified as definite UC and 17% as CD. This reclassification of patients yielded a corrected annual incidence of 12.8 for UC and 6.0 for CD. CONCLUSION: At follow up one to two years after the diagnosis of IBD, the initial incidence was only marginally altered. This is probably due to uniform inclusion criteria and careful diagnostic methods. The study also illustrates the importance of the re-evaluation of the initial diagnosis as close to 10%, both among patients with UC and CD, were reclassified at follow up. 相似文献
12.
L O Schulz 《Journal of the American Dietetic Association》1986,86(12):1702-1704
In February 1985, the National Institutes of Health sponsored the Consensus Development Conference on the Health Implications of Obesity. The panel of experts concluded that height and weight tables based on mortality data and the body mass index (BMI) are helpful measures to determine the presence of obesity and the need for treatment. For the dietitian, however, practical concerns arise regarding which index to select. The usefulness of the BMI in patient education and contradictions between the 1959 and 1983 Metropolitan Life Insurance height-weight tables are discussed. A temporary solution is offered in light of the need for further investigation into morbidity experience at weights recommended in the 1983 table. 相似文献
13.
Stephan Michael Erdmann Bernhardt Sachs Hans F Merk 《American Journal of Contact Dermatitis》2002,13(1):37-38
Phenylephrine is widely used as an ophthalmic drug. However, there are only very few reports on allergic contact dermatitis induced by phenylephrine. In addition, little is known on cross reactivity patterns between the sympathomimetics phenylephrine, epinephrine and ephedrine which share a similar chemical structure. We report on a man who developed allergic contact dermatitis to Neosynerphin POS eyedrops containing phenylephrine hydrochloride. Cross reactivity between phenylephrine, epinephrine and ephedrine was studied by patch testing. Patch tests were performed with the European standard, an ophthalmics and preservatives series, Neosynerphin POS eyedrops, phenylephrine hydrochloride 10% aq., epinephrine and ephedrine (both 1.0 % aq.). Test sites were read after 48, 72 and 168 hours according to the recommendations of the ICDRG. Neosynerphin POS and phenylephrine hydrochloride 10 % aq. gave positive reactions, whereas epinephrine and ephedrine tested negative. Although phenylephrine is an epinephrine analog delayed type hypersensitivity to phenylephrine did not result in cross reactivity with chemically related epinephrine and ephedrine. 相似文献
14.
P M Schulz S C Schulz S C Goldberg P Ettigi R J Resnick R O Friedel 《The Journal of nervous and mental disease》1986,174(8):457-463
Relatives of 22 schizotypal probands were evaluated for lifetime psychiatric diagnoses. Forty-four (N = 44) of the 97 available relatives were interviewed directly using the Diagnostic Interview Schedule. The rates of psychiatric diagnoses were compared with those of sixty-six (N = 66) of 140 relatives of 30 depressed patients. Family history of mental illness was ascertained by the informant method on the remainder of relatives of both proband groups. The rate of depression found in the relatives of schizotypal patients was 52% in those directly interviewed and 25.7% when informants' reports on unavailable relatives are pooled with direct interview data. These rates were not significantly higher than those found for the relatives of depressed probands (34.8% by direct interview and 21% including reports from informants). The high rates of depression in the relatives of schizotypal probands may indicate that schizotypal personality is associated with affective disorder and not only with schizophrenia. However, the high rates may be due to the presence of depressive character traits in relatives, which inflate the rates of dysthymic disorder and other chronic depressive disorders in the relatives of borderline patients. 相似文献
15.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
16.
Sylke Andreas Jörg Dirmaier Timo Harfst Stephan Kawski Uwe Koch Holger Schulz 《European psychiatry》2009,24(2):105-111
The aim of this study was to evaluate a case-mix system to classify inpatients with mental disorders in Germany by means of self-report and expert-rated instruments. The use of case-mix systems enhances the transparency of performance and cost structure and can thus improve the quality of mental health care. We analysed a consecutive sample of 1677 inpatients with mental disorders from 11 hospitals using regression tree analysis. The model assigns patients to 17 groups, accounting for 17% of the variance for duration of stay. Patients with eating disorders had a longer duration of stay than patients with anxiety disorder, duration of mental illness of less than 3–5 years, lower levels of interpersonal problems and higher occupational position. The results showed that besides diagnosis, variables such as duration of illness and interpersonal problems are important for classifying inpatients with mental disorders. The results of the study should be critically reviewed regarding the empirical results of other studies and the appropriateness of case group concepts for inpatients with mental disorders. 相似文献
17.
18.
19.
Israel Liberzon Stephan F Taylor K Luan Phan Jennifer C Britton Lorraine M Fig Joshua A Bueller Robert A Koeppe Jon-Kar Zubieta 《Neuropsychopharmacology》2007,61(9):1030-1038
BACKGROUND: Functional neuroimaging studies have detected abnormal limbic and paralimbic activation to emotional probes in posttraumatic stress disorder (PTSD), but few studies have examined neurochemical mechanisms that underlie functional alterations in regional cerebral blood flow. The mu-opioid neurotransmitter system, implicated in responses to stress and suppression of pain, is distributed in and is thought to regulate the function of brain regions that are implicated in affective processing. METHODS: Here we examined the micro-opioid system with positron emission tomography and the micro-opioid receptor-selective radiotracer [11C] carfentanil in 16 male patients with PTSD and two non-PTSD male control groups, with (n = 14) and without combat exposure (n = 15). Differences in micro-opioid receptor binding potential (BP2) were detected within discrete limbic and paralimbic regions. RESULTS: Relative to healthy controls, both trauma-exposed groups had lower micro-opioid receptor BP2 in extended amygdala, nucleus accumbens, and dorsal frontal and insular cortex but had higher BP2 in the orbitofrontal cortex. PTSD patients exhibited reduced BP2 in anterior cingulate cortex compared with both control groups. Micro-opioid receptor BP2 in combat-exposed subjects without PTSD was lower in the amygdala but higher in the orbitofrontal cortex compared with both PTSD patients and healthy controls. CONCLUSIONS: These findings differentiate the general response of the micro-opioid system to trauma from more specific changes associated with PTSD. 相似文献
20.